Zedsen
Zedsen’s proprietary, non-invasive sensor aims to change the current paradigm of health and oncological care for the better. We are committed to addressing the Institute for Healthcare Improvement’s “Triple Aim'' for optimising healthcare systems, by enhancing the quality of care, improving the health of the overall patient population, and decreasing the cost of healthcare per capita.
Zedsen
Zedsen’s proprietary, non-invasive sensor aims to change the current paradigm of health and oncological care for the better. We are committed to addressing the Institute for Healthcare Improvement’s “Triple Aim'' for optimising healthcare systems, by enhancing the quality of care, improving the health of the overall patient population, and decreasing the cost of healthcare per capita.
TL;DR
Location: London, United Kingdom
Product: Z-Scanner — portable non-invasive electrical capacitance tomography (ECT) device and algorithms
Clinical validation: DiCECT study with Imperial College Healthcare NHS Trust (Charing Cross Hospital) starting Jan 2024
Founded: Circa 2014–2015
Employees: Approximately 20
Company Overview
Problem Domain
Early cancer screening and oncological diagnostics using non-invasive sensing technology.
Founded
2014
Industry
Medical Equipment Manufacturing
Funding Track Record
$12 million
Post-money valuation reported at approximately $110 million
Investor Signal
“Includes individual and institutional backers reported across profiles such as Nasser J. Kazeminy, Joseph R. Grano, Tony Rice, Oppenheimer, and Rubellite Holdings”